FDA Approves LENALIDOMIDE — Sun Pharmaceutical Industries, Inc.

# Sun Pharmaceutical Receives FDA Approval for Generic Lenalidomide Sun Pharmaceutical Industries, Inc. has received FDA approval for its generic version of lenalidomide (ANDA211846), marking a significant entry into the oral immunomodulatory drug market and potentially opening substantial cost-savings opportunities for patients and payers treating multiple myeloma and other blood cancers. The approval could intensify competition in the lenalidomide market and pressure pricing for branded alternatives, while allowing Sun Pharma to capture meaningful market share in this high-value therapeutic segment.